KDR Biologics Sequence Review Report 2026: Vascular endothelial growth factor receptor 2 Similarity and Patent-Risk Signals

This KDR Biologics Sequence Review Report was produced with PatSnap Biology Modality MCP workflows. It turns patent-scale sequence search, sequence retrieval, pairwise alignment and target evidence into a reproducible diligence narrative. Explore the PatSnap MCP servers used in this report.

Review date: 18 August 2026. This report supports R&D, competitive-intelligence and IP triage. It is not a legal opinion, freedom-to-operate conclusion or validity analysis. A sequence hit does not establish infringement, and a no-hit or low-hit result does not establish clearance.

Executive sequence-risk thesis

KDR is a reviewed human protein asset represented by UniProt entry P35968. The reference sequence contains 1,356 amino acids and is annotated as Vascular endothelial growth factor receptor 2. PatSnap’s patent-scale screen returned 89 matching records in the configured result universe. The leading reviewed hit showed 100.00% query identity across 1356/1356, with the database claim annotation recorded as Yes.

The resulting screen is classified as elevated diligence priority. That label prioritizes diligence; it does not classify the asset as blocked, available or unique. Whole-protein identity can be driven by endogenous human sequence, conserved domains, common signal peptides or transmembrane regions. Patent relevance depends on whether live claims cover the complete sequence, a fragment, an engineered variant, an antibody recognizing the target, a use, or a functional genus.

Why this protein is a biologics-relevant review subject

Vascular endothelial growth factor receptor 2 is a traceable cell-surface and secreted human protein sequence suitable for systematic similarity screening. For biologics teams, the sequence can matter in several distinct ways: it may be the administered protein, an extracellular target, an antigen used to raise antibodies, a receptor domain incorporated into a fusion, or a reference against which engineered variants are defined. Those possibilities produce different patent questions even when they share the same gene symbol.

This report therefore separates sequence proximity from legal scope. A close patent-sequence match can identify families worth reading, yet naturally occurring human protein sequence is not itself a conclusion about enforceable rights. Conversely, engineered substitutions, truncations, Fc fusions, linkers, glycosylation-site changes, epitope-defined claims or nucleic-acid delivery constructs may be commercially important even when the full-length reference is not reproduced verbatim.

Biology Modality MCP evidence workflow

The workflow began with ls_sequence_search_submit against ALLPATENT protein records and used ls_sequence_search_get_results to retrieve the leading evidence. ls_sequence_fetch resolved the selected patent-sequence record, and ls_sequence_alignment performed a PSA comparison to the reviewed UniProt query. Finally, ls_antibody_antigen_search tested target-linked antibody evidence and ls_patent_sequence_fetch retrieved sequences from a resolved patent record where available.

Similarity-search readout

The leading result was evaluated under the primary screen using 70–100% identity and 80–100% query coverage. It reported 1356/1356 identical positions, query coverage 1356/1356, subject coverage 1356/1369, E-value 0 and 0/1356 gaps. The database marked the record as Yes for the claim annotation field.

The primary result was obtained inside the predefined strict screening window. That improves reproducibility, but the window still excludes lower-identity functional analogues, short motifs, epitope-only claims, engineered constructs and nucleotide-level variants.

The raw count of 89 records should not be read as the number of independent inventions. One sequence can appear in applications, grants, continuations, divisionals and multiple jurisdictions. It can also recur as a reference, antigen, control or prior-art comparator. Family consolidation by earliest priority, applicant, simple family and legal status is therefore essential before ranking competitive risk.

Sequence fetch and pairwise alignment

ls_sequence_fetch resolved sequence number 1172285 with a length of 1,369 aa, annotated “Protein (human gene KDR post-stop peptide isoform)”. The fetched record was then supplied to ls_sequence_alignment for pairwise comparison with the reviewed KDR sequence.

The PSA returned 1 alignment block(s). The first block covered query positions 1–1,356 and subject positions 1–1,356, with 1,356 identical residues and 0 gaps. Reviewers should map mismatches to extracellular domains, binding interfaces, cleavage sites, transmembrane regions and engineered junctions. A concentrated change at a functional interface can matter more than a similar number of substitutions distributed across a nonfunctional region.

Antibody–antigen and patent-sequence evidence

The exact KDR target-name query returned no antibody–antigen record in the configured page. This is an alias and coverage limitation, not evidence that the target lacks antibody activity or patent disclosure. Follow-up should include the full protein name, synonyms, legacy gene symbols, pathway terminology and therapeutic development codes.

No direct patent sequence bundle was resolved from the leading antibody–antigen record. This does not indicate an empty patent landscape. Relevant families may use different target aliases, functional definitions, percentage-identity language or sequence listings not connected to the first target record.

Target-level evidence complements sequence similarity because biologics patents often define inventions through binding, epitope, function, disease use or combinations rather than an exact full-length target sequence. The strongest review links the returned sequence to a patent family, verifies the role of the sequence in the specification, and then reads live claims in the jurisdictions relevant to development or commercialization.

Patent-risk interpretation

Diligence actions

1. Confirm the exact therapeutic or experimental construct, including isoform, truncation, signal peptide, tags, linkers and fusion partners.
2. Cluster high-ranking sequence records by patent family and earliest priority date rather than counting publications.
3. Retrieve the underlying sequence listings and confirm the biological role of each selected sequence number.
4. Map alignment differences to extracellular domains, binding interfaces, catalytic motifs and engineered junctions.
5. Search KDR, Vascular endothelial growth factor receptor 2 and known aliases in target, antibody, claim and assignee contexts.
6. Build jurisdiction-specific claim charts for live families and document licenses or collaboration rights.
7. Rerun the Biology Modality MCP workflow at the transaction or development decision date because database and legal-status coverage changes.

Bottom line

KDR produced a traceable sequence-search result with 100.00% leading identity, 1356/1356 query coverage, 1 PSA block(s), 0 target-linked antibody records and 0 directly fetched patent sequences. Together, these signals support elevated diligence priority and a prioritized family-and-claim review. They do not support a binary clearance or infringement statement.

Explore PatSnap Open Platform MCP Servers to produce sequence similarity and patent-risk reports for antibodies, proteins, peptides and nucleic-acid assets.

Sources and methodology notes

Reference sequence metadata: reviewed human UniProt entry P35968. Patent-scale similarity, sequence detail, PSA, patent-sequence and antibody–antigen evidence was retrieved through PatSnap Biology Modality MCP on 18 August 2026. Results are bounded by the configured query, thresholds, aliases, task limits and database coverage; rerun at the decision date.